ES2587827T3 - Las pirazoloquinolonas son potentes inhibidores de PARP - Google Patents

Las pirazoloquinolonas son potentes inhibidores de PARP Download PDF

Info

Publication number
ES2587827T3
ES2587827T3 ES12160548.9T ES12160548T ES2587827T3 ES 2587827 T3 ES2587827 T3 ES 2587827T3 ES 12160548 T ES12160548 T ES 12160548T ES 2587827 T3 ES2587827 T3 ES 2587827T3
Authority
ES
Spain
Prior art keywords
isoquinolin
methyl
title compound
dci
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12160548.9T
Other languages
English (en)
Spanish (es)
Inventor
Thomas D. Penning
Gui-Dong Zhu
Virajkumar B. Gandhi
Jianchun Gong
Vincent L. Giranda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Application granted granted Critical
Publication of ES2587827T3 publication Critical patent/ES2587827T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
ES12160548.9T 2006-02-15 2007-02-15 Las pirazoloquinolonas son potentes inhibidores de PARP Active ES2587827T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77351306P 2006-02-15 2006-02-15
US773513P 2006-02-15

Publications (1)

Publication Number Publication Date
ES2587827T3 true ES2587827T3 (es) 2016-10-27

Family

ID=38229340

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12160548.9T Active ES2587827T3 (es) 2006-02-15 2007-02-15 Las pirazoloquinolonas son potentes inhibidores de PARP
ES07757073.7T Active ES2473344T3 (es) 2006-02-15 2007-02-15 Las pirazoloquinolonas son potentes inhibidoras de la PARP

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07757073.7T Active ES2473344T3 (es) 2006-02-15 2007-02-15 Las pirazoloquinolonas son potentes inhibidoras de la PARP

Country Status (18)

Country Link
US (2) US8546368B2 (pt)
EP (2) EP2468748B1 (pt)
JP (1) JP5242419B2 (pt)
KR (1) KR20080094729A (pt)
CN (1) CN101421268B (pt)
AU (1) AU2007214411B2 (pt)
BR (1) BRPI0707902A2 (pt)
CA (1) CA2641776C (pt)
CR (1) CR10277A (pt)
EC (1) ECSP088676A (pt)
ES (2) ES2587827T3 (pt)
GT (1) GT200800158A (pt)
IL (1) IL193272A0 (pt)
NO (1) NO20083923L (pt)
RU (1) RU2008136784A (pt)
TW (1) TW200811173A (pt)
WO (1) WO2007095628A1 (pt)
ZA (1) ZA200806646B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546991A (en) 2003-11-20 2010-01-29 Janssen Pharmaceutica Nv 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors
NZ546990A (en) 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
WO2006003147A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
JP5100376B2 (ja) 2004-06-30 2012-12-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
WO2009118384A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
DK2271626T3 (en) * 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
PL2364983T3 (pl) * 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
WO2010078427A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
CN102325755B (zh) 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102282147B (zh) 2009-01-28 2015-09-30 卡拉治疗学股份有限公司 二环吡唑并-杂环
EP4782062A2 (en) * 2009-12-01 2026-07-29 AbbVie Inc. Novel tricyclic compounds
WO2011147296A1 (zh) * 2010-05-24 2011-12-01 苏州汉德森星湖生物制药有限公司 吡唑衍生物
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
CN112010850A (zh) * 2019-05-31 2020-12-01 江苏天士力帝益药业有限公司 一种parp抑制剂的中间体tsl-1502m及其制备方法
CN114053276B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
CN114053271B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种含有tsl-1502m的药物组合物及其应用
WO2024121264A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives
WO2024121262A1 (en) 2022-12-09 2024-06-13 Syngenta Crop Protection Ag Insecticidal compound based on pyrazole derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601580A (en) 1982-08-18 1986-07-22 University Of Southampton Measurement of oscillatory and vibrational motion
IT1154024B (it) * 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5677309A (en) 1996-03-22 1997-10-14 Neurogen Corporation 1,2,4-triazolo 4,3-c! quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones; a new class of GABA brain receptor ligands
GB2321130B (en) * 1997-12-23 1998-12-23 Bookham Technology Ltd An integrated optical transceiver
JP2000319278A (ja) 1999-05-11 2000-11-21 Ono Pharmaceut Co Ltd 縮合ピラジン化合物およびその化合物を有効成分とする薬剤
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
DE60018216T2 (de) 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
CA2404669A1 (en) * 2000-03-27 2001-10-04 Akiko Asakawa Condensed pyrazole derivatives, process for producing the same and use thereof
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US7222827B2 (en) * 2002-04-19 2007-05-29 Crain Enterprises, Inc. Telescoping leg lock with thumb actuator
ATE540928T1 (de) * 2002-11-22 2012-01-15 Mitsubishi Tanabe Pharma Corp Isochinolinverbindungen und ihre medizinische verwendung
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005087775A1 (ja) 2004-03-15 2005-09-22 Ono Pharmaceutical Co., Ltd. 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物
EP1781300A1 (en) 2004-07-16 2007-05-09 ProteoSys AG Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases
EP1863813A2 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
WO2006112331A1 (ja) 2005-04-13 2006-10-26 Dainippon Simitomo Pharma Co., Ltd. 新規縮合ピロール誘導体
WO2007032466A1 (ja) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. 複素環化合物、その製造方法並びに用途

Also Published As

Publication number Publication date
AU2007214411A1 (en) 2007-08-23
CN101421268B (zh) 2016-01-06
ZA200806646B (en) 2010-01-27
NO20083923L (no) 2008-11-04
US20070249597A1 (en) 2007-10-25
EP1989204B1 (en) 2014-05-21
WO2007095628A1 (en) 2007-08-23
KR20080094729A (ko) 2008-10-23
TW200811173A (en) 2008-03-01
IL193272A0 (en) 2009-02-11
RU2008136784A (ru) 2010-03-20
CR10277A (es) 2008-10-13
US20140213610A1 (en) 2014-07-31
JP2009526869A (ja) 2009-07-23
ES2473344T3 (es) 2014-07-04
US8546368B2 (en) 2013-10-01
EP1989204A1 (en) 2008-11-12
GT200800158A (es) 2009-07-09
AU2007214411B2 (en) 2010-07-01
CA2641776A1 (en) 2007-08-23
EP2468748B1 (en) 2016-05-25
CN101421268A (zh) 2009-04-29
CA2641776C (en) 2014-04-08
JP5242419B2 (ja) 2013-07-24
BRPI0707902A2 (pt) 2011-05-17
ECSP088676A (es) 2008-09-29
EP2468748A1 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
ES2473344T3 (es) Las pirazoloquinolonas son potentes inhibidoras de la PARP
ES2426981T3 (es) 1H-benzimidazol-4-carboxamidas sustituidas con un carbono cuaternario en la posición 2 como inhibidores de PARP para su uso en el tratamiento del cáncer
ES2963417T3 (es) Derivados de imidazol condensados como moduladores de IL-17
AU2016371014B2 (en) Polycyclic TLR7/8 antagonists and use thereof in the treatment of immune disorders
CN119585287A (zh) Kras g12d蛋白水解靶向嵌合体
JP2021046403A (ja) イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用
ES3004333T3 (en) Benzimidazole derivatives and their uses
JP2021533125A (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
CA3164112A1 (en) Pyrazolotriazines
WO2012025811A1 (en) Indolylpyrimidines as modulators of gpr119
ES2656096T3 (es) Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
TW202448898A (zh) 用於egfr激酶降解之化合物
WO2023239846A1 (en) Heterocyclic compounds as pi3kα inhibitors
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
MX2008010465A (en) Pyrazoloquinolones are potent parp inhibitors
AU2012200399B2 (en) 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
BR112020007589B1 (pt) Inibidores da atividade de proteína canal receptor de potencial transiente 6 (trpc6) ou seu sal farmaceuticamente aceitável, seu uso, e composição farmacêutica